Log in to search using one of your social media accounts:

 

Lisdexamfetamine Dimesylate Has Early Benefit in Binge Eating
Improvements in efficacy measures as early as week one favoring lisdexamfetamine dimesylate (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - August 4, 2017 Category: Psychiatry Tags: Pharmacy, Psychiatry, Journal, Source Type: news

Vyvanse vs. Strattera
Title: Vyvanse vs. StratteraCategory: MedicationsCreated: 2/23/2017 12:00:00 AMLast Editorial Review: 2/23/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - February 23, 2017 Category: Drugs & Pharmacology Source Type: news

Vyvanse vs. Adderall
Title: Vyvanse vs. AdderallCategory: MedicationsCreated: 11/14/2016 12:00:00 AMLast Editorial Review: 11/14/2016 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - November 14, 2016 Category: Drugs & Pharmacology Source Type: news

Vyvanse (lisdexamfetamine)
Title: Vyvanse (lisdexamfetamine)Category: MedicationsCreated: 12/10/2008 12:00:00 AMLast Editorial Review: 9/12/2016 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - September 12, 2016 Category: Drugs & Pharmacology Source Type: news

Vyvanse (Lisdexamfetamine Dimesylate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 6, 2016 Category: Drugs & Pharmacology Source Type: news

CBT, Medication Helpful for Binge Eating DisorderCBT, Medication Helpful for Binge Eating Disorder
Therapist-led cognitive-behavioral therapy, second-generation antidepressants, and lisdexamfetamine help reduce binge eating and related psychopathology, an updated review shows. Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - June 30, 2016 Category: Psychiatry Tags: Psychiatry News Source Type: news

Certain Medications, Psychological Therapy May Help Adults with Binge-Eating Disorder (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Lisdexamfetamine, cognitive-behavioral therapy (CBT), and second-generation antidepressants may help treat adults with binge-eating disorder, suggests a meta-analysis in the Annals of Internal Medicine.Researchers examined data from … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 27, 2016 Category: Primary Care Source Type: news

Shire jumps as Vyvanse drug helps it to beat earnings forecast
LONDON (Reuters) - Strong demand for Shire's top-selling Vyvanse drug helped to lift first-quarter earnings by a better than expected 12 percent, boosting the London-listed group's shares ahead of its $32 billion acquisition of U.S. rare diseases specialist Baxalta . (Source: Reuters: Health)
Source: Reuters: Health - April 29, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

How Vyvanse for ADHD Can Interact With Bipolar...
Vyvanse (lisdexamfetamine) is a medication used to treat attention deficit hyperactivity disorder, but it can also interact with bipolar medications. (Source: About.com Bipolar Disorder)
Source: About.com Bipolar Disorder - March 24, 2016 Category: Psychiatry Authors: bipolar.guide at about.com Tags: health Source Type: news

Lisdexamfetamine dimesylate cost effective for binge-eating
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2016 Category: Drugs & Pharmacology Source Type: news

Why Are So Many College and High School Kids Abusing Adderall
During the past 15 years, there has been a remarkable transformation in the drug trade. It used to be dominated by the illegal drug cartels. Now it it is dominated by the legal drug companies. The most dangerous legal drugs are the prescription opioids, now responsible for twice as many deaths as street drugs and also for a secondary epidemic of heroin addiction. The next most dangerous legal drugs are Xanax and other short acting benzodiazepines that potentiate overdoses, cause severe addiction, raise the risk of falls, and worsen cognitive problems. ADHD meds are the most dangerous legal drugs among young people in co...
Source: Science - The Huffington Post - November 9, 2015 Category: Science Source Type: news

Limited Video Game Time Could Help Kids With ADHD, Study Suggests
Children with ADHD (attention deficit hyperactivity disorder) show signs of improvement after playing a videogame for 30 minutes a day rather than taking a pill, the U.S. company developing the treatment said on Wednesday. Diagnoses for ADHD have risen in recent decades, and some 9.5 percent of children aged 3-17 in the United States had the condition in 2012, according to the Center for Disease Control and Prevention. Children in the pilot study - 80 aged between eight and 12, half of which had ADHD - showed improved working memory and levels of attention, and some parent ratings of symptoms also rose, according to the re...
Source: Healthy Living - The Huffington Post - October 28, 2015 Category: Consumer Health News Source Type: news

Limited Video Game Time Could Help Kids With ADHD, Study Suggests
Children with ADHD (attention deficit hyperactivity disorder) show signs of improvement after playing a videogame for 30 minutes a day rather than taking a pill, the U.S. company developing the treatment said on Wednesday. Diagnoses for ADHD have risen in recent decades, and some 9.5 percent of children aged 3-17 in the United States had the condition in 2012, according to the Center for Disease Control and Prevention. Children in the pilot study - 80 aged between eight and 12, half of which had ADHD - showed improved working memory and levels of attention, and some parent ratings of symptoms also rose, according to the re...
Source: Science - The Huffington Post - October 28, 2015 Category: Science Source Type: news

​Here’s a graph that shows how Shire beat sales estimates for its top drug, Vyvanse
Never underestimate the power of a celebrity tennis star to help sell a new drug. One of the more closely-watched metrics today when Shire Pharmaceuticals (Nasdaq: SHPG) reported its financials for the three months that ended in June was sales of its top-selling drug, Vyvanse. The drug for attention deficit hyperactivity disorder earned $1.45 billion in revenues last year, making up nearly a quarter of the company’s total for 2014, and will be a key factor in whether the company attains its stated… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 23, 2015 Category: American Health Authors: Don Seiffert Source Type: news

New Agent May Curb Binge EatingNew Agent May Curb Binge Eating
Compared with placebo, lisdexamfetamine produced greater and speedier improvement in binge eating behavior, body weight, and psychopathology of obsessive-compulsive features of BED. Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - July 9, 2015 Category: Psychiatry Tags: Psychiatry News Source Type: news

Could ADHD Drug Find New Role in Menopause?
Small study suggests Vyvanse might help with concentration, thought organization (Source: WebMD Health)
Source: WebMD Health - June 12, 2015 Category: Consumer Health News Source Type: news

Could ADHD Drug Find New Role in Menopause?
Small study suggests Vyvanse might help with concentration, thought organization Source: HealthDay Related MedlinePlus Pages: Drug Safety, Medicines, Menopause (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 12, 2015 Category: Consumer Health News Source Type: news

Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centers - Kaland ME, Klein-Schwartz W.
CONTEXT: Lisdexamfetamine is a pro-drug stimulant that requires the enzymatic hydrolysis of lysine from dexamphetamine for pharmacologic effects. There is limited information comparing non-therapeutic lisdexamfetamine and dextroamphetamine exposures. ... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - April 10, 2015 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news

New Binge-Eating Disorder Drug Vyvanse: FAQ
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - February 9, 2015 Category: Journals (General) Source Type: news

New Binge-Eating Disorder Drug Vyvanse: FAQ
The FDA has approved the first drug in the U.S. to treat binge-eating disorder, Vyvanse. The agency says it might lessen the number of food binges in people with the condition. (Source: WebMD Health)
Source: WebMD Health - February 4, 2015 Category: Consumer Health News Source Type: news

Monica Seles to help Shire ace marketing of new drug to treat binge-eating disorder
Analysts say that one of the biggest challenges Shire Pharmaceuticals will face in marketing the first-ever drug approved to treat binge-eating disorder is letting people know exactly what the disorder is. To that end, a partnership with former tennis star Monica Seles may help. Last week, Shire announced its top-selling drug for attention-deficit hyperactivity disorder, Vyvanse, had earned additional approval from the U.S. Food and Drug Administration to treat binge eating, which is recognized… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 3, 2015 Category: Biotechnology Authors: Don Seiffert Source Type: news

FDA approves new drug for binge eating disorder (BED)
The United States Food and Drug Administration (FDA) recently approved lisdexamfetamine dimesylate, under the brand name Vyvanse, to treat moderate to severe binge eating disorder (BED) in adults, a first of its kind prescription drug specifically indicated for BED. Experts say that understanding the differences between obesity and BED is important for clinicians, as BED is an eating disorder that affects only a portion of those with the medical disease obesity. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 2, 2015 Category: Science Source Type: news

Vyvanse Approved for Binge-Eating Disorder
(Source: WebMD Health)
Source: WebMD Health - February 2, 2015 Category: Consumer Health News Source Type: news

Binge eating disorder drug made locally gets FDA approval
The Food and Drug Administration has approved Shire's application to market Vyvanse as a treatment for moderate-to-severe binge eating disorder in adults. The drug is already approved for use in patients with attention deficit hyperactive disorder. "Binge eating disorder is the most common adult eating disorder in the United States," said Philip J. Vickers, global head of research and development at Shire, in a prepared statement. "This new indication for Vyvanse is a critical milestone in the… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 2, 2015 Category: Pharmaceuticals Authors: John George Source Type: news

Vyvanse Approved for Binge-Eating Disorder
Characterized by compulsive overeating Source: HealthDay Related MedlinePlus Pages: Eating Disorders, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 2, 2015 Category: Consumer Health News Source Type: news

First Drug Approved for Binge-Eating Disorder (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Lisdexamfetamine dimesylate (Vyvanse), previously approved for treating attention-deficit hyperactivity disorder, is now approved to treat … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 2, 2015 Category: Primary Care Source Type: news

Vyvanse OK'd for Binge Eating
(MedPage Today) -- FDA gives green light for new indication for ADHD drug. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - January 31, 2015 Category: Pediatrics Source Type: news

Business Briefing: F.D.A. Approves a Drug for Binge-Eating Disorder
Federal health regulators have approved Vyvanse, an attention-deficit disorder drug, for a new use as a first-of-its kind treatment for binge-eating disorder. (Source: NYT Health)
Source: NYT Health - January 31, 2015 Category: Consumer Health News Authors: By THE ASSOCIATED PRESS Tags: Eating Disorders Drugs (Pharmaceuticals) Food and Drug Administration Source Type: news

FDA Okays Vyvanse for Binge Eating DisorderFDA Okays Vyvanse for Binge Eating Disorder
The FDA announced it has expanded the use of a drug approved for ADHD to treat binge eating disorder. News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 30, 2015 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

FDA approves Shire's Vyvanse for binge-eating disorder
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Friday approved Shire Plc's stimulant Vyvanse to treat binge-eating disorder, the first product to be approved for the condition. (Source: Reuters: Health)
Source: Reuters: Health - January 30, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

FDA expands uses of Vyvanse to treat binge-eating disorder
The U.S. Food and Drug Administration today expanded the approved uses of Vyvanse (lisdexamfetamine dimesylate) to treat binge-eating disorder in adults. The drug is the first FDA-approved medication to treat this condition. (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 30, 2015 Category: American Health Source Type: news

This Week: Tavenner Out at CMS, Vyvanse Promising for Binge Eating
(MedPage Today) -- Top medical stories during the week of Jan. 12. (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - January 16, 2015 Category: Psychiatry Source Type: news

ADHD drug Lisdexamfetamine dimesylate 'curbs symptoms of disorder'
Scientists at the Lindner Center of HOPE in Ohio discovered the drug lisdexamfetamine dimesylate, a medication approved to treat attention deficit hyperactivity disorder, reduces the urge to eat. (Source: the Mail online | Health)
Source: the Mail online | Health - January 15, 2015 Category: Consumer Health News Source Type: news

An ADHD drug may tame binge eating disorder
Binge eating disorder, a newly recognized condition in which bouts of voracious eating lead to guilt, shame and often obesity, may yield to lisdexamfetamine (marketed as Vyvanse), a medication that has been used for several years to treat attention deficit and hyperactivity disorder in children... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - January 14, 2015 Category: Science Source Type: news

Study: Vyvanse Effective Option for Treating Binge Eating (CME/CE)
(MedPage Today) -- ADHD drug cut binges markedly in randomized trial (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - January 14, 2015 Category: Psychiatry Source Type: news

Shire eating disorder drug gets U.S. priority review
LONDON (Reuters) - Shire's hyperactivity drug Vyvanse will get a priority review in the United States as a potential treatment for binge eating disorder, showing a willingness by U.S. regulators to consider novel ways to fight eating problems. (Source: Reuters: Health)
Source: Reuters: Health - September 15, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Maintenance of wakefulness with lisdexamfetamine dimesylate, compared with placebo and armodafinil in healthy adult males undergoing acute sleep loss - Gasior M, Freeman J, Zammit G, Donnelly P, Gao J, Ferreira-Cornwell MC, Roth T.
This study evaluated daytime alertness and performance with lisdexamfetamine dimesylate during acute sleep loss. In a randomized, double-blind study in healthy adult men (n = 135) undergoing 24-hour sleep loss, the alerting effects of single oral lisdexamf... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - September 6, 2014 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news

Patent win helps Shire as AbbVie plots next bid move
LONDON (Reuters) - Shire , which has spurned a $46 billion takeover offer from U.S. group AbbVie as inadequate, has a new reason to argue it is worth more after a U.S. court backed patent claims on its top-selling drug Vyvanse. (Source: Reuters: Health)
Source: Reuters: Health - June 25, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Shire to Test Its ADHD Drug in 4- to 5-Year-Olds in U.S.Shire to Test Its ADHD Drug in 4- to 5-Year-Olds in U.S.
Shire Plc has agreed to a U.S. Food and Drug Administration request to study its stimulant Vyvanse in preschool children as concern rises over the diagnosis and treatment of attention deficit hyperactivity disorder. Reuters Health Information (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 16, 2014 Category: Drugs & Pharmacology Tags: Psychiatry News Source Type: news

Shire to test its ADHD drug in 4 to 5-year olds in U.S.
WASHINGTON (Reuters) - Shire Plc SHP.L has agreed to a U.S. Food and Drug Administration request to study its stimulant Vyvanse in preschool children as concern rises over the diagnosis and treatment of attention deficit hyperactivity disorder, the drugmaker said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - June 13, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Shire agrees to test its ADHD drug in preschool children
LONDON (Reuters) - London-listed drugmaker Shire PLC said it had agreed to a request from the U.S. regulator to test the use of its amphetamine-based drug Vyvanse in preschool children aged four and five with hyperactivity. (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Changes to legislation: tramadol, lisdexamfetamine, zopiclone and zaleplon
Changes to legislation affecting tramadol, lisdexamfetamine, zopiclone and zaleplon have come into force today (10th June 2014). Further information on the changes including professional guidance and frequently asked questions is available in our recently published (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - June 9, 2014 Category: Drugs & Pharmacology Source Type: news

ADHD Treatment Associated with Lower Smoking Rates
Treating attention deficit hyperactivity disorder (ADHD) with stimulant medication may reduce smoking risk, especially when medication is taken consistently, according to an analysis. ADHD is a common childhood disorder that can continue through adolescence and adulthood, and is characterized by hyperactivity, difficulty paying attention and impulsivity. It is most commonly treated with stimulant medication (such as Vyvanse or Concerta), as well as with behavior therapy or a combination of the two. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 12, 2014 Category: Science Source Type: news

Stimulant drug may help women cope with post-menopausal memory lapses
The psychostimulant drug lisdexamfetamine can aid post-menopausal women by improving attention and concentration, organization, working memory and recall, preliminary evidence from a recent study indicates. The study enrolled 30 women between the ages of 48 and 60 who had experienced a diminished ability to focus and multi-task in their early post-menopausal years. The cohort was made up of successful women -- none of whom were more than five years post-menopause. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 5, 2014 Category: Science Source Type: news

Shire's Vyvanse fails endpoint in two Phase III major depressive disorder studies
Shire has reported that Vyvanse did not meet the primary efficacy endpoint versus placebo in two pivotal Phase III investigational trials evaluating the efficacy and safety of Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) to treat major depres… (Source: Drug Development Technology)
Source: Drug Development Technology - February 10, 2014 Category: Pharmaceuticals Source Type: news

Must-read: The NY Times on the marketing of ADHD drugs
This article, although it really doesn’t feature a smoking gun, is important reading. Highly recommended.     (Source: The Poison Review)
Source: The Poison Review - December 16, 2013 Category: Toxicology Authors: Leon Tags: Medical adderall ADHD attention deficit hyperactivity disorder concerta intuniv marketing new york times Ritalin Source Type: news

ADHD Drug Curbs Binge Eating
(MedPage Today) -- Patients with binge eating disorder showed a significant decrease in bingeing episodes while taking lisdexamfetamine dimesylate (Vyvanse) compared with placebo in two identical phase III trials, the drug's manufacturer said. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - November 6, 2013 Category: Pediatrics Source Type: news

Positive top-line results shown for Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) in adults with binge eating disorder
Shire plc (LSE: SHP, NASDAQ: SHPG) announces positive top-line results from two identically designed randomized placebo-controlled Phase 3 studies evaluating the efficacy and safety of Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) versus placebo in adults with binge eating disorder (BED). In both studies Vyvanse was found to be statistically superior to placebo on the primary efficacy analysis (p-value "We are extremely pleased with these results, and will be working expeditiously to submit an application to the U.S... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 6, 2013 Category: Consumer Health News Tags: Eating Disorders Source Type: news

Shire's ADHD drug succeeds in trial to treat binge eating
LONDON (Reuters) - Pharmaceutical group Shire PLC said Vyvanse, its amphetamine-based drug prescribed to U.S. students to control ADHD, had also been successful in treating the newly-recognized binge eating disorder (BED) in a trial. (Source: Reuters: Health)
Source: Reuters: Health - November 5, 2013 Category: Consumer Health News Tags: healthNews Source Type: news